Mortimer Joanne E, Taylor Marie E
Eastern Virginia Medical School, Department of Medicine, Division of Medical Oncology, Norfolk, Virginia, USA.
Breast Cancer Res. 2003;5(6):329-31. doi: 10.1186/bcr725. Epub 2003 Oct 13.
Preclinical studies suggest that 18F-2-deoxy-2-fluoro-D-glucose (18F-FDG) kills breast cancer cells without significant marrow toxicity or parenchymal toxicity. Radiation dose calculations estimated from fluorodeoxyglucose positron emission tomography images in women with metastatic disease indicate that 18F-FDG should be a feasible and safe option in humans. Because the available radiotherapeutic agents, strontium 89 and samarium 153 provide palliation to a limited population of women with bony metastases, new radiopharmaceutical agents with broader applicability are needed. The development of 18F-FDG as the first positron-emitting radiotherapeutic has the potential to be an innovative treatment, not only in osteoblastic disease, but also in osteolytic disease and in soft tissue metastases.
临床前研究表明，18F-2-脱氧-2-氟-D-葡萄糖（18F-FDG）可杀死乳腺癌细胞，且无明显的骨髓毒性或实质毒性。根据转移性疾病女性患者的氟脱氧葡萄糖正电子发射断层扫描图像估算的辐射剂量表明，18F-FDG对人类而言应是一种可行且安全的选择。由于现有的放射治疗药物锶89和钐153仅能为有限的骨转移女性患者提供缓解，因此需要具有更广泛适用性的新型放射性药物。18F-FDG作为首个正电子发射放射治疗药物的研发，不仅在成骨性疾病中，而且在溶骨性疾病和软组织转移中都有可能成为一种创新疗法。
